<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pathology of mediastinal tumors
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pathology of mediastinal tumors
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pathology of mediastinal tumors
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Henry D Tazelaar, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anja C Roden, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Nicholson, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rogerio C Lilenbaum, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mediastinal tumors are among the most difficult lesions examined by the surgical pathologist for several reasons. First, many different types of lesions occur in this location  (
         <a class="graphic graphic_figure graphicRef53534" href="/z/d/graphic/53534.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_table graphicRef121021" href="/z/d/graphic/121021.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Second, biopsies often consist of small, crushed specimens. Third, few pathologists have significant experience with mediastinal pathology because specimens from this location are relatively uncommon.
        </p>
        <p>
         Since many tumors that occur in the mediastinum have overlapping histologic features, one must consider a broad differential diagnosis and perform a thorough evaluation of each specimen, which may include ancillary testing. This is important since therapy for various mediastinal tumors differs considerably and may significantly impact survival. Additionally, it may not be apparent whether the tumor is arising in the mediastinum or from adjacent lung, or might be metastatic to the mediastinum.
        </p>
        <p>
         Interpretation of pathologic specimens from the mediastinum requires familiarity with a wide range of neoplasms and careful clinical correlation. It is critical for surgeons, radiologists, and pathologists to communicate well. If tumors originally treated by nonsurgical means do not respond as expected, additional biopsies, special studies, or consultations may be necessary to achieve the correct diagnosis.
        </p>
        <p>
         The pathology of mediastinal tumors is reviewed here. The clinical evaluation of mediastinal masses is discussed elsewhere, and clinical and management issues of the specific tumor types are reviewed in the relevant topics.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6967.html" rel="external">
          "Approach to the adult patient with a mediastinal mass"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4619.html" rel="external">
          "Clinical presentation and management of thymoma and thymic carcinoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16667.html" rel="external">
          "Thymic neuroendocrine (carcinoid) tumors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">
          "Clinical presentation and initial evaluation of non-Hodgkin lymphoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4691.html" rel="external">
          "Hodgkin lymphoma: Epidemiology and risk factors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ISSUES WITH EXAMINATION OF SPECIMENS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obtaining an adequate biopsy specimen can be a problem in the diagnosis of mediastinal tumors. As some mediastinal tumors are not treated surgically (eg, lymphoma) or undergo neoadjuvant therapy before resection, diagnosis is often attempted with core needle or minimally invasive surgical biopsies. Biopsies may be nondiagnostic because the lesion is not sampled adequately or because crush artifact or extensive necrosis, fibrosis, or cystic change obscures the diagnostic lesion. (See
         <a class="medical medical_review" href="/z/d/html/6967.html" rel="external">
          "Approach to the adult patient with a mediastinal mass"
         </a>
         .)
        </p>
        <p>
         Intraoperative frozen sections are often used in the setting of surgical procedures:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To determine if diagnostic tissue has been obtained
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To establish the diagnosis so that optimal surgical treatment can be rendered
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To assess resection margins and stage of the tumor
        </p>
        <p>
        </p>
        <p>
         While some tumors can readily be diagnosed by frozen section, there are many "mimickers" in mediastinal pathology that can cause diagnostic difficulties [
         <a href="#rid2">
          2
         </a>
         ]. Frozen section processing may introduce artifacts. Therefore, additional tissue that is not submitted for frozen sectioning may be necessary in some cases. If the tumor is extensively fibrotic or necrotic, generous sampling may avoid the need for additional biopsy procedures. It can be useful to set aside a piece of tumor to be snap-frozen for certain molecular and/or genetic analysis.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          THYMOMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thymomas are malignant epithelial neoplasms arising in the thymus; these tumors are commonly located in the prevascular mediastinum [
         <a href="#rid3">
          3,4
         </a>
         ]. However, thymomas can also be found in other regions of the mediastinum, the neck, pulmonary hilum, thyroid gland, lung, pleura, or pericardium [
         <a href="#rid5">
          5-8
         </a>
         ].
        </p>
        <p>
         The clinical features, diagnostic evaluation, and treatment of thymoma, including thymic carcinoma, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4619.html" rel="external">
          "Clinical presentation and management of thymoma and thymic carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H733363315">
         <span class="h2">
          Assessment of resection specimen
         </span>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Gross appearance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Grossly, most thymomas are circumscribed, tan, firm masses  (
         <a class="graphic graphic_picture graphicRef132476" href="/z/d/graphic/132476.html" rel="external">
          picture 1
         </a>
         ). They may range from microscopic lesions to tumors over 30 centimeters in diameter. The cut surface is often lobulated, with bands of fibrous stroma  (
         <a class="graphic graphic_picture graphicRef132477" href="/z/d/graphic/132477.html" rel="external">
          picture 2
         </a>
         ). Cystic changes may be extensive, and in such cases, the cyst wall should be sampled carefully to search for tumor foci.
        </p>
        <p>
         Thymomas can be encapsulated, invade the surrounding mediastinal adipose tissue with or without invasion of the mediastinal pleura, or extend beyond the mediastinal pleura into lungs, pericardium, heart, large vessels, and/or involve the phrenic nerves. They may also be found as implants along the pleura, pericardium, and/or diaphragm. The extent of invasion forms the basis of current tumor, node, metastasis staging. Good communication is necessary between surgeon and pathologist, which includes orientation of the specimen by the surgeon so that margins can be appropriately evaluated and any anatomic structure removed in addition to the thymus (eg, pericardium, mediastinal pleura, phrenic nerve, large vessels) can be adequately identified.
        </p>
        <p>
         For precise staging, all regional lymph nodes need to be sampled from the thymectomy specimen. Separately submitted lymph nodes, appropriately site-identified, are also desirable.
        </p>
        <p class="headingAnchor" id="H2751608701">
         <span class="h3">
          Classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical relevance of the World Health Organization (WHO) classification system has been validated by many studies [
         <a href="#rid9">
          9,10
         </a>
         ]. However, the prognostic significance may not apply to all subtypes, as some studies have shown a similar clinical outcome for type A and B1 and possibly B2 thymomas, while type B3 thymomas typically have a more adverse outcome [
         <a href="#rid11">
          11
         </a>
         ]. Moreover, staging and possibly degree of resection (complete versus partial) are stronger prognostic parameters for thymomas [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="local">
          'Staging of thymic tumors'
         </a>
         below and
         <a class="local">
          'Prognostic implications'
         </a>
         below.)
        </p>
        <p>
         The WHO morphologic classification of thymomas is as follows  (
         <a class="graphic graphic_table graphicRef121024" href="/z/d/graphic/121024.html" rel="external">
          table 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type A thymomas account for 11.5 percent of all thymomas [
         <a href="#rid13">
          13
         </a>
         ]. They are composed of bland spindle cells and possibly a few scattered lymphocytes  (
         <a class="graphic graphic_picture graphicRef121149" href="/z/d/graphic/121149.html" rel="external">
          picture 3
         </a>
         ). Sixty percent of patients present at stage I [
         <a href="#rid4">
          4
         </a>
         ]. Atypical type A thymomas are morphologically reminiscent of type A thymomas but show hypercellularity, increased mitotic activity, and/or necrosis [
         <a href="#rid4">
          4
         </a>
         ]. In particular, necrosis appears to be correlated with advanced stage [
         <a href="#rid14">
          14,15
         </a>
         ]; however, these findings still need to be validated. Similar findings can also rarely be seen in type AB thymomas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type AB thymomas account for 25 percent of all thymomas [
         <a href="#rid13">
          13
         </a>
         ]. They are a mixture of type A and type B1 or B2 thymoma  (
         <a class="graphic graphic_picture graphicRef120982" href="/z/d/graphic/120982.html" rel="external">
          picture 4
         </a>
         ). A thymoma that is predominantly comprised of type A morphology but contains ≥10 percent area of terminal deoxynucleotidyl transferase (TdT)-positive lymphocytes should be classified as type AB thymoma. The components are either intermixed or distinct. Sixty-seven percent of patients present at stage I.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type B1 thymomas account for 17.5 percent of all thymomas [
         <a href="#rid13">
          13
         </a>
         ]. They are predominantly comprised of lymphocytes with only scattered epithelial cells, typically not forming clusters or only clusters of two epithelial cells  (
         <a class="graphic graphic_picture graphicRef120979" href="/z/d/graphic/120979.html" rel="external">
          picture 5
         </a>
         ). Type B1 thymomas contain paler medullary islands with or without Hassall corpuscle-like elements. Fifty percent of patients present at stage I.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type B2 thymomas account for 26 percent of all thymomas [
         <a href="#rid13">
          13
         </a>
         ]. They contain more epithelial cells, often forming clusters of more than two epithelial cells  (
         <a class="graphic graphic_picture graphicRef120980" href="/z/d/graphic/120980.html" rel="external">
          picture 6
         </a>
         ). Although unusual, medullary islands may be present. In addition, the cytologic atypia of the tumor cells in B2 thymomas can be more pronounced and may even show anaplastic features. Thirty-two percent of patients present at stage I.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type B3 thymomas account for 16 to 21 percent of all thymomas [
         <a href="#rid13">
          13
         </a>
         ]. They are predominantly comprised of large, polygonal tumor cells that may show increased cytologic atypia and only a few or no scattered lymphocytes. Perivascular spaces are usually present  (
         <a class="graphic graphic_picture graphicRef132478" href="/z/d/graphic/132478.html" rel="external">
          picture 7
         </a>
         ). These thymomas have a prognosis that is worse than that of other thymomas but better than thymic carcinomas, with only 19 percent of patients presenting at stage I [
         <a href="#rid4">
          4,10
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Histologic heterogeneity is common, with more than one histologic subtype frequently present in one tumor. Therefore, subtyping of thymomas is not performed on biopsies (except for a diagnosis of carcinoma, as discussed below). (See
         <a class="local">
          'Thymic carcinoma'
         </a>
         below.)
        </p>
        <p>
         In resection specimens, all histologic components of a thymoma should be reported in 10-percent increments, starting with the most prominent component (except for type AB thymomas, thymomas with carcinoma component [combined thymic carcinoma], and thymomas with carcinoid component [combined carcinoid]) [
         <a href="#rid4">
          4
         </a>
         ]. In combined thymic carcinomas and carcinoids, the carcinoma or carcinoid component, respectively, should be mentioned first independent of the percentage of that component.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Histology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thymomas are characterized by a lobulated architecture. Cellular lobules are comprised of various proportions of neoplastic epithelial cells and reactive thymocytes. The lobules are intersected by fibrous bands  (
         <a class="graphic graphic_picture graphicRef132477" href="/z/d/graphic/132477.html" rel="external">
          picture 2
         </a>
         ). Many thymomas are at least partially surrounded by a fibrous capsule.
        </p>
        <p>
         Thymomas are morphologically classified according to the WHO based on the shape of the epithelial tumor cells, the ratio of tumor cells to thymocytes, and the cytologic atypia of tumor cells  (
         <a class="graphic graphic_table graphicRef121024" href="/z/d/graphic/121024.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Classification'
         </a>
         above.)
        </p>
        <p>
         Growth patterns that can be particularly seen in type A and AB thymoma or micronodular thymoma with lymphoid stroma include microcystic changes, storiform growth, staghorn-shaped vessels resembling those seen in solitary fibrous tumors, rosettes similar to neuroendocrine tumors, gland-like structures, or a papillary growth pattern [
         <a href="#rid4">
          4,16,17
         </a>
         ]. Prominent plasma cell infiltrates, microcystic patterns, and prominent myoid cells (rhabdomyomatous thymoma) may be encountered [
         <a href="#rid18">
          18,19
         </a>
         ]. Dilated perivascular spaces can occur in type B1, B2, and B3 thymoma [
         <a href="#rid17">
          17,20
         </a>
         ]. The spaces are filled by plasma fluid and may contain a few lymphocytes, plasma cells, or foamy macrophages  (
         <a class="graphic graphic_picture graphicRef132478" href="/z/d/graphic/132478.html" rel="external">
          picture 7
         </a>
         ). Small vessels with hyalinized walls are often present in the center of these spaces. Neoplastic cells surrounding these spaces may show a palisading arrangement. Other histologic features seen in thymomas include Hassall corpuscles (specifically in type B1  (
         <a class="graphic graphic_picture graphicRef120979" href="/z/d/graphic/120979.html" rel="external">
          picture 5
         </a>
         ) but also some B2 thymomas) and a "starry-sky" pattern [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         Sometimes the distinction between type B1 and B2 thymomas can be difficult. While both are lymphocyte-rich thymomas, type B1 thymomas contain areas of medullary differentiation (medullary islands) and only scattered epithelial cells without clustering (&lt;3 contiguous epithelial cells), while type B2 thymomas contain more epithelial cells that frequently cluster (≥3 continuous epithelial cells)  (
         <a class="graphic graphic_picture graphicRef120980" href="/z/d/graphic/120980.html" rel="external">
          picture 6
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. Type B1 thymomas can also be mistaken for small lymphocytic lymphomas, specifically on small biopsies. Recognition of a meshwork of epithelial cells can be facilitated by the use of a keratin stain  (
         <a class="graphic graphic_picture graphicRef120981" href="/z/d/graphic/120981.html" rel="external">
          picture 8
         </a>
         ). Type B3 thymomas  (
         <a class="graphic graphic_picture graphicRef132478" href="/z/d/graphic/132478.html" rel="external">
          picture 7
         </a>
         ) (and occasionally even type A or atypical A thymomas) may be confused with thymic carcinomas or squamous cell carcinoma metastatic from other sites. While thymomas have a preserved lobulated architecture, thymic carcinomas exhibit a distorted architecture with variably sized cell nests and possibly even single cells in a desmoplastic stromal reaction. Thymomas can show extensive cystic changes or may be associated with a thymic cyst  (
         <a class="graphic graphic_picture graphicRef132479" href="/z/d/graphic/132479.html" rel="external">
          picture 9
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1348681047">
         <span class="h3">
          Molecular findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thymomas have an unusually low mutational burden for malignant tumors [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         The most common mutations in thymic epithelial tumors (TET; thymomas and thymic carcinomas) include mutations in the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         General transcription factor II-i (
         <em>
          GTF2I
         </em>
         ; 39 to 42 percent of cases)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In TET,
         <em>
          GTF2I
         </em>
         mutations are missense mutations in codon L424H, which appears to be unique to TET [
         <a href="#rid21">
          21
         </a>
         ]. However, the pathogenetic significance of that mutation of the gene is largely unknown.
         <em>
          GTF2I
         </em>
         mutations are most common in type A (82 to 100 percent) and AB thymomas (70 to 79 percent), followed by B1 (0 to 32 percent), B2 (0 to 22 percent), and B3 (10 to 21 percent) thymomas. They are only rarely found in thymic carcinomas (0 to 8 percent) [
         <a href="#rid4">
          4,21,22
         </a>
         ]. In TET,
         <em>
          GTF2I
         </em>
         mutation has been identified as an independent favorable prognostic factor [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor protein p53 (
         <em>
          TP53
         </em>
         ; 25 to 36 percent),
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          KIT
         </em>
         (6 to 20 percent of carcinomas), and
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cyclin-dependent kinase inhibitor 2A (
         <em>
          CDKN2A
         </em>
         ; 11 to 38 percent of thymic carcinomas, also in rare B3 thymomas)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Various TETs may harbor mastermind-like transcriptional coactivator 2 (
         <em>
          MAML2)
         </em>
         rearrangements including a subset of thymic mucoepidermoid carcinomas, metaplastic thymomas (due to
         <em>
          YAP1-MAML2
         </em>
         gene fusion), and a small subset of B2 and B3 thymomas (due to
         <em>
          KMT2A-MAML2
         </em>
         gene fusion) [
         <a href="#rid23">
          23-27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a few cases, mutations in the neuroblastoma RAS viral oncogene homolog (
         <em>
          NRAS
         </em>
         ), Kirsten rat sarcoma viral oncogene homolog (
         <em>
          KRAS
         </em>
         ), cyclin D1 (
         <em>
          CCND1
         </em>
         ), anaplastic lymphoma kinase (
         <em>
          ALK
         </em>
         ), Ataxia-Telangiectasia mutated (
         <em>
          ATM
         </em>
         ), avian erythroblastic leukemia viral oncogene homolog 4 (
         <em>
          ERBB4
         </em>
         ), fibroblast growth factor receptor 3 (
         <em>
          FGFR3
         </em>
         ), SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (
         <em>
          SMARCB1
         </em>
         ), and serine/threonine-protein kinase 11 (
         <em>
          STK11
         </em>
         ) genes have been identified [
         <a href="#rid21">
          21,22,28-32
         </a>
         ]. Furthermore, thymic hyalinizing clear cell carcinoma with EWS RNA-binding protein 1 (
         <em>
          EWSR1
         </em>
         ) translocation has been described [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4270095306">
         <span class="h3">
          Immunohistochemistry
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thymic epithelial cells stain for epithelial markers such as keratins, epithelial membrane antigen, p63, p40, and usually paired box 8 (PAX8; polyclonal antibody) [
         <a href="#rid34">
          34
         </a>
         ]. Thymic lymphocytes mark with TdT, cluster of differentiation (CD)1a, CD3, CD5, CD45, and CD99 [
         <a href="#rid35">
          35,36
         </a>
         ]. In a subset of type A and AB thymomas, neoplastic epithelial cells also stain for CD20 and rarely thyroid transcription factor-1 (TTF-1) [
         <a href="#rid37">
          37,38
         </a>
         ]. (See
         <a class="local">
          'Classification'
         </a>
         above.)
        </p>
        <p>
         Differentiation between thymomas and thymic carcinomas is discussed below. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Prognostic implications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although some multivariate analyses suggest that staging is the most important prognostic factor [
         <a href="#rid12">
          12,39,40
         </a>
         ], the prognosis is probably multifactorial, with histologic features, staging, and completeness of resection contributing to the clinical behavior of these tumors [
         <a href="#rid10">
          10,12,41-43
         </a>
         ]. This is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4619.html" rel="external">
          "Clinical presentation and management of thymoma and thymic carcinoma", section on 'Prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          THYMIC CARCINOMA
         </span>
        </p>
        <p class="headingAnchor" id="H2365164141">
         <span class="h2">
          Assessment of resection specimen
         </span>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Gross appearance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thymic carcinomas are commonly large, firm, infiltrating masses, with frequent areas of cystic change and necrosis [
         <a href="#rid44">
          44
         </a>
         ]. These tumors are encapsulated in 15 percent of cases or less [
         <a href="#rid45">
          45
         </a>
         ]. A mucoid cut surface is described in mucoepidermoid carcinomas [
         <a href="#rid46">
          46
         </a>
         ]. Multilocular thymic cysts have been reported in association with mucoepidermoid carcinomas and basaloid carcinomas [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2172988787">
         <span class="h3">
          Classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         The World Health Organization morphologic classification of thymic carcinomas is included in the table  (
         <a class="graphic graphic_table graphicRef121024" href="/z/d/graphic/121024.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Histology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thymic carcinomas are cytologically malignant  (
         <a class="graphic graphic_picture graphicRef120983" href="/z/d/graphic/120983.html" rel="external">
          picture 10
         </a>
         ) and may manifest cystic changes. While a certain amount of necrosis, atypia, and mitoses can be encountered in occasional thymomas, these findings are common in thymic carcinomas. An infiltrative growth pattern associated with desmoplastic stroma is often seen, without evidence of immature T lymphocytes. The lymphocytes exhibit the phenotype of mature T cells (terminal deoxynucleotidyl transferase [TdT] negative, cluster of differentiation [CD]1a negative, CD3 positive, and CD4 positive or CD8 positive). B cells and plasma cells are also seen.
        </p>
        <p>
         Thymic carcinomas display a variety of histologic subtypes  (
         <a class="graphic graphic_table graphicRef121030" href="/z/d/graphic/121030.html" rel="external">
          table 3
         </a>
         ), emphasizing the ability of thymic epithelium to differentiate in a variety of directions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Squamous cell carcinoma
         </strong>
         – Squamous cell carcinomas are by far the most common thymic carcinomas. They morphologically resemble squamous cell carcinomas elsewhere  (
         <a class="graphic graphic_picture graphicRef120983" href="/z/d/graphic/120983.html" rel="external">
          picture 10
         </a>
         ). They can be keratinizing or nonkeratinizing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Basaloid carcinoma
         </strong>
         – This tumor is composed of neoplastic basaloid cells that are characterized by a high nuclear-cytoplasmic ratio. The neoplastic cells grow in nests or line small cystic spaces. Peripheral palisading is a characteristic feature.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lymphoepithelial carcinoma
         </strong>
         – This tumor is composed of cytologically malignant, large, polygonal cells with prominent nucleoli that often grow in a syncytial pattern, in sheets and nests. A dense lymphoplasmacytic infiltrate is present and may obscure the tumor cells  (
         <a class="graphic graphic_picture graphicRef140194" href="/z/d/graphic/140194.html" rel="external">
          picture 11
         </a>
         and
         <a class="graphic graphic_picture graphicRef140196" href="/z/d/graphic/140196.html" rel="external">
          picture 12
         </a>
         ). This carcinoma has the morphology of nasopharyngeal lymphoepithelial carcinoma, and Epstein-Barr virus has been implicated in its pathogenesis and can be identified at least in a subset of these cases  (
         <a class="graphic graphic_picture graphicRef140202" href="/z/d/graphic/140202.html" rel="external">
          picture 13
         </a>
         ) [
         <a href="#rid48">
          48,49
         </a>
         ]. Lymphoepithelial carcinoma is highly aggressive and associated with a poor prognosis [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3404.html" rel="external">
          "Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma", section on 'Epstein-Barr virus'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3404.html" rel="external">
          "Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma", section on 'Histology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NUT carcinoma of the thorax
         </strong>
         – Nuclear protein of the testis (NUT) carcinomas are rare but very aggressive carcinomas. Fifty-one percent of patients have metastases at time of presentation, and the outcome is usually fatal with a median overall survival of 6.7 months. These tumors have a midline predominance (90 percent) and occur most commonly in the thorax (57 percent). There is no sex predilection, and the median age ranges between 16 and 50 years old (age range, 0.1 to 78 years). These tumors are considered an aggressive subset of squamous cell carcinoma [
         <a href="#rid50">
          50-54
         </a>
         ]. A NUT immunostain shows a speckled nuclear expression pattern  (
         <a class="graphic graphic_picture graphicRef140200" href="/z/d/graphic/140200.html" rel="external">
          picture 14
         </a>
         and
         <a class="graphic graphic_picture graphicRef140199" href="/z/d/graphic/140199.html" rel="external">
          picture 15
         </a>
         ) [
         <a href="#rid55">
          55
         </a>
         ]; other immunostains are listed in the table  (
         <a class="graphic graphic_table graphicRef121031" href="/z/d/graphic/121031.html" rel="external">
          table 4
         </a>
         ). These tumors are characterized by rearrangement of the
         <em>
          NUT
         </em>
         gene
         <em>
          (NUTM1)
         </em>
         most commonly (70 percent of cases) and bromodomain-containing protein (
         <em>
          BRD)4-NUT
         </em>
         - t(15;19)(q14;p13.1); other rearrangements such as
         <em>
          BRD3-NUT
         </em>
         or
         <em>
          NUT
         </em>
         -variant fusions have also been identified [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clear cell carcinoma
         </strong>
         – This tumor is comprised of islands and trabeculae of neoplastic cells with clear cytoplasm [
         <a href="#rid57">
          57
         </a>
         ] set in fibrous stroma; some show more extensive hyalinization around the tumor cell islands, similar to hyalinizing clear cell carcinomas of salivary glands and lung. In these tumors, EWS RNA-binding protein 1 (
         <em>
          EWSR1
         </em>
         ) translocation has been identified and these tumors have been termed hyalinizing clear cell carcinoma [
         <a href="#rid33">
          33
         </a>
         ]. While clear cell carcinomas are exceedingly rare, they are associated with a poor prognosis due to local recurrence or metastatic disease [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low-grade papillary adenocarcinoma of the thymus
         </strong>
         – These tumors are characterized by cuboidal or polygonal cells with only mild atypia, small nucleoli, and a small amount of cytoplasm growing in tubulopapillary pattern. Fibrovascular cores are identified in the papillary structures. These tumors may be associated with type A or AB thymomas [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mucoepidermoid carcinoma
         </strong>
         – Mucoepidermoid carcinomas are composed of intermediate cells (polygonal cells with eosinophilic cytoplasm, small round nuclei, and inconspicuous nucleoli), squamous cells, and mucin-producing (goblet) cells  (
         <a class="graphic graphic_picture graphicRef140198" href="/z/d/graphic/140198.html" rel="external">
          picture 16
         </a>
         ). Mucoepidermoid carcinomas can be low or high grade [
         <a href="#rid46">
          46
         </a>
         ]. Mastermind-like transcriptional coactivator 2 (
         <em>
          MAML2)
         </em>
         rearrangement is disease defining and has been shown in 50 to 56 percent of thymic mucoepidermoid carcinomas [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Enteric-type adenocarcinoma of the thymus
         </strong>
         – This tumor morphologically and immunophenotypically mimics colorectal adenocarcinoma. It is characterized by a mucinous or tubulopapillary morphology  (
         <a class="graphic graphic_picture graphicRef132509" href="/z/d/graphic/132509.html" rel="external">
          picture 17
         </a>
         ) or clusters of tumor cells floating in extracellular mucin. Intracytoplasmic mucin may also be seen. The tumor cells exhibit an enteric phenotype with expression of at least one of the markers cytokeratin (CK)20, CDX2, and mucin (MUC)2; expression of CK7 or CD5 may be present, while thyroid transcription factor 1 (TTF-1) and CD117 are negative [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adenocarcinoma, not otherwise specified
         </strong>
         – These carcinomas are characterized by glandular differentiation and/or intracytoplasmic mucin but do not exhibit features of low-grade papillary adenocarcinoma or enteric-type adenocarcinoma [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sarcomatoid carcinoma
         </strong>
         – Sarcomatoid carcinomas are composed in part or completely of spindled epithelial cells. When tumors show heterologous components such as rhabdomyoblastic or cartilaginous differentiation [
         <a href="#rid59">
          59
         </a>
         ], they are classified as carcinosarcomas. The differential diagnosis of sarcomatoid carcinoma includes synovial sarcoma of the mediastinum [
         <a href="#rid60">
          60
         </a>
         ]. Identification of t(X; 18)(p11.2;q11.2),
         <em>
          SYT-SSX1
         </em>
         , or
         <em>
          SYT-SSX2
         </em>
         gene fusion or expression of SS18-SSX fusion antibodies can help confirm the diagnosis of synovial sarcoma [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Undifferentiated carcinoma
         </strong>
         – Undifferentiated carcinoma is composed of sheets of undifferentiated cells, the epithelial nature of which should be documented by immunohistochemistry [
         <a href="#rid4">
          4
         </a>
         ]  (
         <a class="graphic graphic_picture graphicRef79276" href="/z/d/graphic/79276.html" rel="external">
          picture 18
         </a>
         ). Germ cell tumors and metastatic malignant melanoma should be excluded.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2366546235">
         <span class="h3">
          Molecular findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common mutations in thymic epithelial tumors (thymomas and thymic carcinomas) are discussed above and summarized in an update from an expert group [
         <a href="#rid62">
          62
         </a>
         ]. (See
         <a class="local">
          'Molecular findings'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2693326404">
         <span class="h3">
          Immunohistochemistry
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some stains may be useful in distinguishing thymic carcinoma from other entities  (
         <a class="graphic graphic_table graphicRef121031" href="/z/d/graphic/121031.html" rel="external">
          table 4
         </a>
         ). This is discussed in detail below. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis includes metastatic carcinoma to mediastinal lymph nodes. Because the morphology of thymic carcinoma is similar to features of these tumors elsewhere, their distinction from metastatic disease can be challenging. Ultimately, the distinction between thymic carcinoma and metastatic disease requires clinicoradiologic correlation and the clinical exclusion of metastatic disease [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p>
         Thymic carcinoma has a morphology and biology that is distinct from thymoma; nevertheless, differentiating a thymic carcinoma from a thymoma can be problematic.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinically, thymic carcinoma is usually not associated with paraneoplastic syndromes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         On histologic examination,
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thymic carcinoma does not have an immature T lymphocytic component, although B lymphocytes, plasma cells, or mature T lymphocytes can be found within the stroma.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The lobulated pattern of thymoma, separated by thick fibrous bands, is not found in thymic carcinoma, which displays a desmoplastic stroma. Moreover, histologic features characteristic of thymoma, such as perivascular spaces, medullary differentiation, and Hassall corpuscles, are not seen in thymic carcinomas.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Carcinoma and thymoma may be found synchronously, or carcinoma may develop within a pre-existing thymoma [
         <a href="#rid65">
          65
         </a>
         ]. These tumors are reported as combined carcinomas, and both the thymoma and the carcinoma components should be reported starting with the carcinoma component [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunohistochemical findings include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Expression of cluster of differentiation (CD)5 and CD117 might be helpful to distinguish thymic carcinoma from thymoma, as these markers are only rarely expressed in thymomas but are expressed in the majority of thymic squamous cell carcinomas [
         <a href="#rid38">
          38,66-68
         </a>
         ]. Furthermore, loss of expression of
         <em>
          BRCA
         </em>
         -associated protein-1 (BAP1) and/or mTAP indicates carcinoma and argues against thymoma [
         <a href="#rid68">
          68
         </a>
         ]. Indeed, a panel of CD117 (expression in &gt;10 percent of tumor cells), Tdt, BAP1, and mTAP has recently been suggested as useful in the distinction of thymic carcinoma from thymoma [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A combination of CD5, CD117, and paired box 8 (PAX8, polyclonal) might be helpful specifically in the distinction of thymic squamous cell carcinomas (dual expression of CD5 and CD117 with or without PAX8) from pulmonary squamous cell carcinomas, although none of these stains appear specific to thymic carcinoma [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Prognostic implications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histologic subtype of thymic carcinoma may have some prognostic significance with NUT carcinoma, lymphoepithelial carcinoma, sarcomatoid carcinoma, undifferentiated carcinoma, clear cell carcinoma, and poorly differentiated squamous cell carcinoma having in general a worse prognosis [
         <a href="#rid4">
          4,44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          THYMIC NEUROENDOCRINE TUMORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Twenty-five percent of thymic neuroendocrine tumors arise in the setting of multiple endocrine neoplasia, type 1 (MEN-1) syndrome [
         <a href="#rid69">
          69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">
          "Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         The histologic diagnosis is based upon recognition of neuroendocrine features such as organoid nests, trabeculae, rosettes, or palisading and homogeneous cytologic features with finely granular nuclear chromatin  (
         <a class="graphic graphic_picture graphicRef120985" href="/z/d/graphic/120985.html" rel="external">
          picture 19
         </a>
         and
         <a class="graphic graphic_picture graphicRef120986" href="/z/d/graphic/120986.html" rel="external">
          picture 20
         </a>
         and
         <a class="graphic graphic_picture graphicRef120987" href="/z/d/graphic/120987.html" rel="external">
          picture 21
         </a>
         ).
        </p>
        <p>
         Further details regarding the histology, clinical presentation, differential diagnosis, and treatment, are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16667.html" rel="external">
          "Thymic neuroendocrine (carcinoid) tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2961983060">
         <span class="h1">
          STAGING OF THYMIC TUMORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thymomas, thymic carcinomas, and thymic neuroendocrine tumors are staged according to the tumor, node, metastasis staging of the American Joint Committee on Cancer/Union for International Cancer Control  (
         <a class="graphic graphic_table graphicRef111399" href="/z/d/graphic/111399.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid70">
          70
         </a>
         ]. Other staging systems, including the Masaoka staging system, are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4619.html" rel="external">
          "Clinical presentation and management of thymoma and thymic carcinoma", section on 'Staging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          GERM CELL TUMORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mediastinal germ cell tumors (GCTs) can occur as primary neoplasms in the mediastinum. Whether these tumors represent a malignant transformation of germ cells migrating along the midline during embryogenesis or originate from the primordial cells of the thymus with germ cell potential is still a subject of debate. The close association of mediastinal GCTs with the thymus and the presence of placental-like alkaline phosphatase (PLAP)-positive cells within the normal thymus support a potential thymic etiology [
         <a href="#rid71">
          71,72
         </a>
         ].
        </p>
        <p>
         The clinical manifestations, diagnosis, and treatment of extragonadal GCTs arising in the mediastinum are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2998.html" rel="external">
          "Extragonadal germ cell tumors involving the mediastinum and retroperitoneum"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Histologic subtypes
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histologic types of GCTs in the mediastinum are similar to those that occur in the testis and ovary  (
         <a class="graphic graphic_table graphicRef121032" href="/z/d/graphic/121032.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid73">
          73,74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3236.html" rel="external">
          "Ovarian germ cell tumors: Pathology, epidemiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">
          "Anatomy and pathology of testicular tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Mature teratoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mature teratomas are often cystic. They occur in all age groups but are most frequently seen in adolescents.
        </p>
        <p>
         Grossly, mature teratomas are tan, soft, cystic structures measuring from 3 to 21 cm in greatest diameter  (
         <a class="graphic graphic_picture graphicRef132510" href="/z/d/graphic/132510.html" rel="external">
          picture 22
         </a>
         ) [
         <a href="#rid73">
          73
         </a>
         ]. Histologically, they are composed of adult-type tissue derived from the three embryonic layers (mesoderm, endoderm, and ectoderm  (
         <a class="graphic graphic_picture graphicRef132511" href="/z/d/graphic/132511.html" rel="external">
          picture 23
         </a>
         )). Mature teratomas are negative for 12p overrepresentation [
         <a href="#rid75">
          75
         </a>
         ]. They should be distinguished from bronchogenic cysts (which are composed of respiratory epithelium), seromucinous glands, smooth muscle, and/or cartilage, which are all tissues that may be seen in large airways but lack other elements.
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Immature teratomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Macroscopically, immature teratomas form often cystic masses with areas of hemorrhage and necrosis. Histologically, they are characterized by mature elements from all three germ layers mixed with immature embryonic tissue  (
         <a class="graphic graphic_picture graphicRef54587" href="/z/d/graphic/54587.html" rel="external">
          picture 24
         </a>
         ). While endodermal, ectodermal, and mesodermal tissues displaying various stages of maturation are found within these tumors, immature neuroectodermal elements predominate. This component consists of rosettes and neuroepithelium-forming tubules, some of which may even contain melanin pigment.
        </p>
        <p>
         Evidence suggests that there are two possible distinct pathways to the development of teratomas in the mediastinum [
         <a href="#rid76">
          76
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Benign teratomas that exhibit organoid growth, without cytologic atypia, and no 12p aberrations are thought to arise from benign precursor cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignant teratomas that show cytologic atypia and often have increased chromosome 12p copy numbers are likely derived from malignantly transformed precursor cells. While benign teratomas can occur in children, females, and males, malignant teratomas are, in general, seen in postpubertal males.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          Seminomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seminomas are found predominantly in postpubertal males  (
         <a class="graphic graphic_table graphicRef121032" href="/z/d/graphic/121032.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         Grossly, mediastinal seminomas are large, solid, soft, and tan masses with a lobulated appearance on cut surface [
         <a href="#rid78">
          78
         </a>
         ]. Histologically, seminomas have a characteristic nested pattern comprised of epithelioid tumor cells that are surrounded by a thin fibrovascular stroma, which frequently contains scattered lymphocytes  (
         <a class="graphic graphic_picture graphicRef120988" href="/z/d/graphic/120988.html" rel="external">
          picture 25
         </a>
         ). The tumor cells have abundant cytoplasm, which is usually clear, and the nuclei have a vesicular chromatin pattern; nucleoli may be prominent. In the mediastinum, seminomas have some characteristic features  (
         <a class="graphic graphic_picture graphicRef120988" href="/z/d/graphic/120988.html" rel="external">
          picture 25
         </a>
         and
         <a class="graphic graphic_table graphicRef121032" href="/z/d/graphic/121032.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid74">
          74,78
         </a>
         ]. The differential diagnosis of seminomas includes thymoma and thymic cyst, nodular-sclerosing Hodgkin lymphoma, reactive lymphoid hyperplasia, and infection (granulomatous inflammation).
        </p>
        <p>
         Approximately 8 to 20 percent of mediastinal seminomas can present as multiloculated, cystic masses up to 19 cm in diameter [
         <a href="#rid79">
          79,80
         </a>
         ]. These tumors generally occur in asymptomatic young males and seem to be associated with a good prognosis [
         <a href="#rid80">
          80
         </a>
         ]. Histologically, these cystic lesions consist of a multilocular thymic cyst lined by squamous or cuboidal epithelium with seminomatous tumor cells present in the wall of the cyst.
        </p>
        <p>
         Immunohistochemical study of seminomas is summarized in the table  (
         <a class="graphic graphic_table graphicRef121032" href="/z/d/graphic/121032.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid81">
          81
         </a>
         ]. Beta-human chorionic gonadotropin (beta-hCG) is positive in 3 to 17 percent of cases, while alpha fetoprotein (AFP) is almost invariably negative. The D2-40 stain is also positive in extragonadal seminomas [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h3">
          Nonseminomatous GCTs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonseminomatous germ cell tumors (GCTs) include yolk sac tumors, embryonal carcinomas, choriocarcinomas, and mixed GCTs.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Yolk sac tumor
         </strong>
         – Yolk sac tumor primarily affects young males, but rare cases in females and children have been reported. Typically, serum AFP concentrations are elevated, although that is not entirely specific [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Grossly, yolk sac tumors are large, necrotic, and hemorrhagic masses that invade adjacent structures. Histologically, mediastinal yolk sac tumors can grow in many patterns  (
         <a class="graphic graphic_picture graphicRef132512" href="/z/d/graphic/132512.html" rel="external">
          picture 26
         </a>
         ). Immunohistochemistry studies are summarized in the table  (
         <a class="graphic graphic_table graphicRef121032" href="/z/d/graphic/121032.html" rel="external">
          table 6
         </a>
         ). Beta-hCG is almost always negative [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Embryonal carcinoma
         </strong>
         – Embryonal carcinoma is a rare, highly malignant neoplasm that seldom presents in a pure form [
         <a href="#rid84">
          84
         </a>
         ]. Grossly, embryonal carcinoma often presents as a large, solid mass, with foci of hemorrhage and necrosis. It may invade adjacent structures. Morphologic features are noted in the table  (
         <a class="graphic graphic_table graphicRef121032" href="/z/d/graphic/121032.html" rel="external">
          table 6
         </a>
         ). Syncytiotrophoblastic giant cells are found scattered within the tumor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Neoplastic cells in embryonal carcinoma are keratin positive  (
         <a class="graphic graphic_table graphicRef121032" href="/z/d/graphic/121032.html" rel="external">
          table 6
         </a>
         ). PLAP has a variable immunoreactivity, and AFP and beta-hCG are each typically positive in one-quarter to one-third of cases, respectively [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choriocarcinoma
         </strong>
         – Choriocarcinoma is a highly malignant GCT that mainly affects young males and is often found in association with other GCTs, particularly embryonal carcinoma. Gynecomastia and elevated serum beta-hCG are characteristic, and most patients present with intra- or extrathoracic metastasis at the time of diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Grossly, choriocarcinoma is a large, soft, characteristically hemorrhagic and partially necrotic mass [
         <a href="#rid85">
          85
         </a>
         ]. A biphasic cell population composed of cytotrophoblasts and syncytiotrophoblasts is characteristic  (
         <a class="graphic graphic_table graphicRef121032" href="/z/d/graphic/121032.html" rel="external">
          table 6
         </a>
         ). The former are mononuclear, round cells with clear cytoplasm, atypical nuclei, and prominent nucleoli, while the latter population consists of large, atypical, multinucleated giant cells found in clusters throughout the tumor and around hemorrhagic and necrotic lakes  (
         <a class="graphic graphic_picture graphicRef132513" href="/z/d/graphic/132513.html" rel="external">
          picture 27
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Immunohistochemical staining reveals reactivity for keratin almost universally  (
         <a class="graphic graphic_table graphicRef121032" href="/z/d/graphic/121032.html" rel="external">
          table 6
         </a>
         ). Beta-hCG is always positive in the syncytiotrophoblastic component [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Malignant mixed GCTs
         </strong>
         – Malignant mixed GCTs are composed of a combination of two or more histologic types of GCT [
         <a href="#rid86">
          86
         </a>
         ]. The prognosis depends upon the histologic components of the tumor; thus, the pathology report should include the approximate percentage of each histologic type of GCT.
        </p>
        <p>
        </p>
        <p>
         Somatic or hematologic malignancies can arise in GCTs. In fact, a sarcomatoid component is most frequently seen in primary mediastinal GCTs and is more commonly found in mature teratomas than immature teratomas, choriocarcinomas, yolk sac tumors, and seminomas. Rhabdomyosarcoma components are also more common than angiosarcoma, leiomyosarcoma, glioblastoma, malignant peripheral nerve sheath tumor, epithelioid hemangioendothelioma, or undifferentiated sarcoma components. It is important to diagnose such tumors as primary mediastinal GCTs with sarcomatoid component, as they are usually unresponsive to conventional chemotherapy and have a dismal prognosis. It is recommended to estimate the involved sarcomatous area. Primary mediastinal GCTs with sarcomatoid component have a worse prognosis than their gonadal counterpart. Only 18 percent of patients are alive at 12 to 42 months; 82 percent die from disease from 1 to 37 months [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
         These features can be difficult to discern on biopsies, and a high level of suspicion has to be maintained with a low threshold to perform GCT markers and chromosome 12p analysis. Chromosome 12p abnormalities are common in primary mediastinal GCT and in one study were found in 22 (of 23) mediastinal seminomas by fluorescence in-situ hybridization including amplification and i12p [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
         There is no official staging system of primary mediastinal GCT, although a proposed system has been published [
         <a href="#rid4">
          4,74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          LYMPHOMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of lymphomas can present in the mediastinum, either alone or as a clinically significant component of more widespread disease. These tumors are discussed elsewhere and include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hodgkin lymphoma (see
         <a class="medical medical_review" href="/z/d/html/4688.html" rel="external">
          "Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults"
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse large B cell lymphoma (see
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma"
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary mediastinal large B cell lymphoma (see
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Primary mediastinal large B cell lymphoma'
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphoblastic leukemia/lymphoma (see
         <a class="medical medical_review" href="/z/d/html/4686.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15773.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma"
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mucosa-associated lymphoid tissue lymphoma (see
         <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21210364">
         <span class="h1">
          MESENCHYMAL TUMORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Either benign or malignant, mesenchymal tumors are rare mediastinal neoplasms (less than 2 percent  (
         <a class="graphic graphic_table graphicRef121035" href="/z/d/graphic/121035.html" rel="external">
          table 7
         </a>
         )) [
         <a href="#rid89">
          89,90
         </a>
         ]. The symptoms are identical to those of other mediastinal masses, and the pathologic features are similar to those of other tumors of soft tissue occurring at other sites. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Introduction'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurogenic tumors
         </strong>
         – Mediastinal neurogenic tumors represent 19 to 39 percent of all mediastinal tumors and develop from local peripheral nerves, sympathetic and parasympathetic ganglia, and embryonic remnants of the neural tube. They are most frequent in the paravertebral/posterior compartment of the mediastinum, where they can cause neurologic symptoms by compression [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Schwannomas
         </strong>
         – A variety of benign and malignant tumors of peripheral nerve origin can occur in the mediastinum, among which schwannoma is the most common  (
         <a class="graphic graphic_table graphicRef121035" href="/z/d/graphic/121035.html" rel="external">
          table 7
         </a>
         ). Mediastinal schwannomas are benign neoplasms that originate from Schwann cells and affect patients of both sexes, predominantly in the third and fourth decades of life [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Mediastinal schwannomas are most often asymptomatic, but signs of nerve compression and paralysis, Pancoast syndrome, and Horner syndrome can occur. Computed tomography reveals a round, well-circumscribed mass located in the paravertebral region or intercostal spaces. Focal calcifications and cystic changes are frequent. A characteristic clinicoradiologic feature of these tumors is their extension through an intervertebral foramen, resulting in dumbbell-shaped tumors, and neurologic symptoms of spinal cord compression. (See
         <a class="medical medical_review" href="/z/d/html/4605.html" rel="external">
          "Superior pulmonary sulcus (Pancoast) tumors"
         </a>
         .)
        </p>
        <p>
         Grossly, schwannomas are encapsulated, solid, soft, yellow-pink nodules, with the capsule attached to the epineurium of the nerve that gives rise to the neoplasm. Microscopically, they are composed of spindle cells with elongated nuclei, forming interlacing bundles with focal nuclear palisading (Verocay bodies  (
         <a class="graphic graphic_picture graphicRef60032" href="/z/d/graphic/60032.html" rel="external">
          picture 28
         </a>
         )). A combination of hypercellular (Antoni A pattern) and hypocellular (Antoni B pattern) areas is characteristic. Nuclear atypia  (
         <a class="graphic graphic_picture graphicRef71835" href="/z/d/graphic/71835.html" rel="external">
          picture 29
         </a>
         ) and stromal sclerosis can be seen in older lesions ("ancient" schwannomas). Mitotic figures are rare. Immunohistochemical studies reveal a strongly positive reaction with S-100 protein.
        </p>
        <p class="bulletIndent1">
         Mediastinal schwannomas are cured by surgical resection. (See
         <a class="medical medical_review" href="/z/d/html/6967.html" rel="external">
          "Approach to the adult patient with a mediastinal mass", section on 'Surgical resection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Paragangliomas
         </strong>
         – Paragangliomas are rare mediastinal tumors that usually originate from sympathetic ganglia and commonly secrete catecholamines. Mediastinal paraganglioma are most commonly located beneath the aortic arch above the left atrium and adjacent to the ascending aorta and trachea [
         <a href="#rid92">
          92
         </a>
         ]. Although many behave in a benign fashion, one-quarter of the patients have synchronous or metachronous metastases [
         <a href="#rid92">
          92,93
         </a>
         ]. Over one-half of the tumors harbor pathogenic mutations, most commonly mutations in one of the serine dehydratase (
         <em>
          SDH
         </em>
         ) genes including
         <em>
          SDHB
         </em>
         ,
         <em>
          SDHC
         </em>
         , and
         <em>
          SDHD
         </em>
         , and most of the patients have the same
         <em>
          SDH
         </em>
         germline mutation
         <em>
          .
         </em>
         Pathogenic mutations in the alpha-thalassemia (
         <em>
          ATRX
         </em>
         ), telomerase reverse transcriptase (
         <em>
          TERT
         </em>
         ), or tumor protein p53 (
         <em>
          TP53
         </em>
         ) genes have also been identified. These tumors can occur sporadically or as part of a hereditary syndrome including von Hippel-Lindau, multiple endocrine neoplasia, or succinate dehydrogenase mutation syndrome [
         <a href="#rid94">
          94,95
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Paragangliomas are usually well defined and highly vascularized tumors that morphologically are composed of bland-appearing epithelioid cells forming "Zellballen"  (
         <a class="graphic graphic_picture graphicRef140201" href="/z/d/graphic/140201.html" rel="external">
          picture 30
         </a>
         ). The neoplastic cells express neuroendocrine markers such as synaptophysin and chromogranin but lack staining with keratins. Sustentacular cells can be highlighted by S100 protein.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Others
         </strong>
         – Other neurogenic tumors in the mediastinum include neurofibroma, ganglioneuroma, ganglioneuroblastoma, and neuroblastoma.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H645408766">
         <span class="h1">
          THORACIC SMARCA4-DEFICIENT UNDIFFERENTIATED TUMOR
         </span>
         <span class="headingEndMark">
          —
         </span>
         SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4 (
         <em>
          SMARCA4
         </em>
         )-deficient undifferentiated tumors were introduced in the 2021 World Health Organization classification. While they can occur anywhere in the body, they are seen in the mediastinum. The median age of the patients is 59 years (range, 44 to 76 years) with a male predominance. The median survival has been reported to be approximately seven months [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Histology
         </strong>
         – Morphologically and phenotypically they may present with sarcomatous or carcinomatous features. Some show at least focal rhabdoid morphology  (
         <a class="graphic graphic_picture graphicRef132514" href="/z/d/graphic/132514.html" rel="external">
          picture 31
         </a>
         ) [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunohistochemistry
         </strong>
         – Loss of
         <em>
          SMARCA4
         </em>
         (
         <em>
          BRG1
         </em>
         ) expression is diagnostic in these very aggressive tumors  (
         <a class="graphic graphic_picture graphicRef132515" href="/z/d/graphic/132515.html" rel="external">
          picture 32
         </a>
         ) [
         <a href="#rid96">
          96
         </a>
         ]. In
         <em>
          SMARCA4
         </em>
         -deficient undifferentiated tumors, cytokeratin expression may be present in rare neoplastic cells in 83 percent of the cases [
         <a href="#rid97">
          97
         </a>
         ]. Rarely, thyroid transcription factor-1 (TTF-1) may also be expressed in a few tumor cells. Cluster of differentiation (CD)34, SRY-box transcription factor 2 (SOX2), and spalt-like transcription factor 4 (SALL4) are often expressed, while the tumors fail to express desmin, nuclear protein of the testis (NUT), and S100.
         <em>
          SMARCB2
         </em>
         (
         <em>
          BRM
         </em>
         ) expression is also lost in most of these cases, while expression of SMARCB1 (INI-1) is preserved.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Mediastinal tumors are among the most difficult lesions examined by the surgical pathologist. Interpretation of pathologic specimens from the mediastinum requires familiarity with a wide range of neoplasms and careful clinical correlation. If tumors originally treated by nonsurgical means do not respond as expected, additional biopsies, special studies, or consultations may be necessary to achieve the correct diagnosis. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6967.html" rel="external">
          "Approach to the adult patient with a mediastinal mass"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Examination of specimens
         </strong>
         – Although frozen sections may be used intraoperatively for diagnosis, nonfrozen tissue should always be submitted for routine analysis and potential molecular studies. (See
         <a class="local">
          'Issues with examination of specimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thymoma
         </strong>
         – Thymomas are malignant epithelial neoplasms arising in the thymus, commonly located in the prevascular mediastinum, though they may also occur in other locations. They are typically lobulated in architecture and have an unusually low mutational burden  (
         <a class="graphic graphic_picture graphicRef120979" href="/z/d/graphic/120979.html" rel="external">
          picture 5
         </a>
         and
         <a class="graphic graphic_picture graphicRef120980" href="/z/d/graphic/120980.html" rel="external">
          picture 6
         </a>
         and
         <a class="graphic graphic_picture graphicRef120981" href="/z/d/graphic/120981.html" rel="external">
          picture 8
         </a>
         and
         <a class="graphic graphic_picture graphicRef120982" href="/z/d/graphic/120982.html" rel="external">
          picture 4
         </a>
         and
         <a class="graphic graphic_picture graphicRef132477" href="/z/d/graphic/132477.html" rel="external">
          picture 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef132478" href="/z/d/graphic/132478.html" rel="external">
          picture 7
         </a>
         ). (See
         <a class="local">
          'Thymoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thymic carcinoma
         </strong>
         – Thymic carcinoma has a morphology and biology that are distinct from thymoma. It lacks the lobulated architecture of thymomas and is characterized by cytoarchitectural features of carcinoma similar to those seen in other organs  (
         <a class="graphic graphic_picture graphicRef120983" href="/z/d/graphic/120983.html" rel="external">
          picture 10
         </a>
         and
         <a class="graphic graphic_picture graphicRef79276" href="/z/d/graphic/79276.html" rel="external">
          picture 18
         </a>
         ). The differential diagnosis includes metastatic carcinoma to mediastinal lymph nodes. (See
         <a class="local">
          'Thymic carcinoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thymic neuroendocrine tumors
         </strong>
         – Thymic neuroendocrine tumors are rare tumors, the histologic diagnosis of which is based upon recognition of neuroendocrine features such as organoid nests, trabeculae, rosettes, or palisading and homogeneous cytologic features with finely granular nuclear chromatin  (
         <a class="graphic graphic_picture graphicRef120985" href="/z/d/graphic/120985.html" rel="external">
          picture 19
         </a>
         and
         <a class="graphic graphic_picture graphicRef120986" href="/z/d/graphic/120986.html" rel="external">
          picture 20
         </a>
         and
         <a class="graphic graphic_picture graphicRef120987" href="/z/d/graphic/120987.html" rel="external">
          picture 21
         </a>
         ). These tumors are associated with multiple endocrine neoplasia, type 1 (
         <em>
          MEN1
         </em>
         ) in approximately 25 percent of cases. (See
         <a class="local">
          'Thymic neuroendocrine tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Germ cell tumors
         </strong>
         – Mediastinal germ cell tumors (GCTs) can occur as primary neoplasms in the mediastinum. The histologic subtypes are mature or immature teratomas, seminomas, and nonseminomatous GCTs  (
         <a class="graphic graphic_picture graphicRef54587" href="/z/d/graphic/54587.html" rel="external">
          picture 24
         </a>
         and
         <a class="graphic graphic_picture graphicRef120988" href="/z/d/graphic/120988.html" rel="external">
          picture 25
         </a>
         and
         <a class="graphic graphic_picture graphicRef54661" href="/z/d/graphic/54661.html" rel="external">
          picture 33
         </a>
         and
         <a class="graphic graphic_picture graphicRef132510" href="/z/d/graphic/132510.html" rel="external">
          picture 22
         </a>
         and
         <a class="graphic graphic_picture graphicRef132511" href="/z/d/graphic/132511.html" rel="external">
          picture 23
         </a>
         and
         <a class="graphic graphic_picture graphicRef132512" href="/z/d/graphic/132512.html" rel="external">
          picture 26
         </a>
         and
         <a class="graphic graphic_picture graphicRef132513" href="/z/d/graphic/132513.html" rel="external">
          picture 27
         </a>
         ). (See
         <a class="local">
          'Histologic subtypes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lymphoma
         </strong>
         – A variety of lymphomas can present in the mediastinum, either alone or as a clinically significant component of more widespread disease. (See
         <a class="local">
          'Lymphoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurogenic tumors
         </strong>
         – Neurogenic tumors develop from mediastinal peripheral nerves, sympathetic and parasympathetic ganglia, and embryonic remnants of the neural tube  (
         <a class="graphic graphic_picture graphicRef60032" href="/z/d/graphic/60032.html" rel="external">
          picture 28
         </a>
         and
         <a class="graphic graphic_picture graphicRef71835" href="/z/d/graphic/71835.html" rel="external">
          picture 29
         </a>
         ). They are most frequent in the paravertebral compartment of the mediastinum, where they can cause neurologic symptoms by compression. They include schwannomas and others. (See
         <a class="local">
          'Mesenchymal tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mesenchymal tumors
         </strong>
         – Mesenchymal tumors are rare mediastinal neoplasms that may be either benign or malignant, with pathologic features that are similar to those of other tumors of soft tissue occurring at other sites. (See
         <a class="local">
          'Thoracic SMARCA4-deficient undifferentiated tumor'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5547722">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Mojgan Devouassoux-Shisheboran, MD, and William D Travis, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Roden AC, Fang W, Shen Y, et al. Distribution of Mediastinal Lesions Across Multi-Institutional, International, Radiology Databases. J Thorac Oncol 2020; 15:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jüttner FM, Fellbaum C, Popper H, et al. Pitfalls in intraoperative frozen section histology of mediastinal neoplasms. Eur J Cardiothorac Surg 1990; 4:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carter BW, Benveniste MF, Madan R, et al. ITMIG Classification of Mediastinal Compartments and Multidisciplinary Approach to Mediastinal Masses. Radiographics 2017; 37:413.
          </a>
         </li>
         <li class="breakAll">
          Thoracic Tumors, 5th ed, WHO Classification of Tumors Editorial Board (Ed), IARC, 2021. Vol 5.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran CA, Suster S, Fishback NF, Koss MN. Primary intrapulmonary thymoma. A clinicopathologic and immunohistochemical study of eight cases. Am J Surg Pathol 1995; 19:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran CA, Travis WD, Rosado-de-Christenson M, et al. Thymomas presenting as pleural tumors. Report of eight cases. Am J Surg Pathol 1992; 16:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hino H, Nitadori JI, Ohno K, et al. An Unusual Invasive Ectopic Thymoma in the Thyroid and Anterior Mediastinum. Ann Thorac Surg 2018; 106:e65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peel JK, Prisman E, Ng TL, McGuire AL. Ectopic thymoma managed by neck dissection &amp; video-assisted thoracoscopic thymectomy. J Thorac Dis 2017; 9:E1050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen G, Marx A, Chen WH, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002; 95:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roden AC, Yi ES, Jenkins SM, et al. Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on prognosis. Am J Surg Pathol 2015; 39:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalabreysse L, Roy P, Cordier JF, et al. Correlation of the WHO schema for the classification of thymic epithelial neoplasms with prognosis: a retrospective study of 90 tumors. Am J Surg Pathol 2002; 26:1605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roden AC, Yi ES, Jenkins SM, et al. Modified Masaoka stage and size are independent prognostic predictors in thymoma and modified Masaoka stage is superior to histopathologic classifications. J Thorac Oncol 2015; 10:691.
          </a>
         </li>
         <li class="breakAll">
          WHO Classification of Tumours 5th Edition: Thoracic Tumors, World Health Organization (Ed), 2021.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green AC, Marx A, Ströbel P, et al. Type A and AB thymomas: histological features associated with increased stage. Histopathology 2015; 66:884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vladislav IT, Gökmen-Polar Y, Kesler KA, et al. The role of histology in predicting recurrence of type A thymomas: a clinicopathologic correlation of 23 cases. Mod Pathol 2013; 26:1059.
          </a>
         </li>
         <li class="breakAll">
          Pathology of the Thymus and Mediastinum, 1st ed, WB Saunders, Philadelphia 1995.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marx A, Chan JK, Coindre JM, et al. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol 2015; 10:1383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran CA, Suster S, Koss MN. Plasma cell-rich thymoma. Am J Clin Pathol 1994; 102:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran CA, Koss MN. Rhabdomyomatous thymoma. Am J Surg Pathol 1993; 17:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis JE, Wick MR, Scheithauer BW, et al. Thymoma. A clinicopathologic review. Cancer 1987; 60:2727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radovich M, Pickering CR, Felau I, et al. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell 2018; 33:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng Y, Lei Y, Wu X, et al. GTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis. Lung Cancer 2017; 110:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massoth LR, Hung YP, Dias-Santagata D, et al. Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A-MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma. JCO Precis Oncol 2020; 4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vivero M, Davineni P, Nardi V, et al. Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions. Mod Pathol 2020; 33:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roden AC, Erickson-Johnson MR, Yi ES, García JJ. Analysis of MAML2 rearrangement in mucoepidermoid carcinoma of the thymus. Hum Pathol 2013; 44:2799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murase T, Nakano S, Sakane T, et al. Thymic Mucoepidermoid Carcinoma: A Clinicopathologic and Molecular Study. Am J Surg Pathol 2022; 46:1160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao J, Zhao R, Xiang C, et al. YAP1-MAML2 Fusion as a Diagnostic Biomarker for Metaplastic Thymoma. Front Oncol 2021; 11:692283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aesif SW, Aubry MC, Yi ES, et al. Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas. J Thorac Oncol 2017; 12:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schirosi L, Nannini N, Nicoli D, et al. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann Oncol 2012; 23:2409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petrini I, Meltzer PS, Zucali PA, et al. Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell Death Dis 2012; 3:e351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enkner F, Pichlhöfer B, Zaharie AT, et al. Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets. Pathol Oncol Res 2017; 23:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiseo M, Damato A, Longo L, et al. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs). Lung Cancer 2017; 104:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porubsky S, Rudolph B, Rückert JC, et al. EWSR1 translocation in primary hyalinising clear cell carcinoma of the thymus. Histopathology 2019; 75:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kodama T, Watanabe S, Sato Y, et al. An immunohistochemical study of thymic epithelial tumors. I. Epithelial component. Am J Surg Pathol 1986; 10:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan JK, Tsang WY, Seneviratne S, Pau MY. The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors. Am J Surg Pathol 1995; 19:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato Y, Watanabe S, Mukai K, et al. An immunohistochemical study of thymic epithelial tumors. II. Lymphoid component. Am J Surg Pathol 1986; 10:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith T, Mauri F, Naresh KN. Thyroid transcription factor-1 immunostaining in World Health Organization type AB thymoma. Histopathology 2016; 68:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marx A, Ströbel P, Badve SS, et al. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol 2014; 9:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koga K, Matsuno Y, Noguchi M, et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 1994; 44:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kornstein MJ, Curran WJ Jr, Turrisi AT 3rd, Brooks JJ. Cortical versus medullary thymomas: a useful morphologic distinction? Hum Pathol 1988; 19:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas de Montpréville V, Ghigna MR, Lacroix L, et al. Thymic carcinomas: clinicopathologic study of 37 cases from a single institution. Virchows Arch 2013; 462:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moser B, Scharitzer M, Hacker S, et al. Thymomas and thymic carcinomas: prognostic factors and multimodal management. Thorac Cardiovasc Surg 2014; 62:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg 2004; 77:1860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer 1991; 67:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Truong LD, Mody DR, Cagle PT, et al. Thymic carcinoma. A clinicopathologic study of 13 cases. Am J Surg Pathol 1990; 14:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran CA, Suster S. Mucoepidermoid carcinomas of the thymus. A clinicopathologic study of six cases. Am J Surg Pathol 1995; 19:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iezzoni JC, Gaffey MJ, Weiss LM. The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas. Am J Clin Pathol 1995; 103:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leyvraz S, Henle W, Chahinian AP, et al. Association of Epstein-Barr virus with thymic carcinoma. N Engl J Med 1985; 312:1296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomez JMD, Syed G, Co MLF, et al. A rare highly aggressive tumour: lymphoepithelioma-like thymic carcinoma. BMJ Case Rep 2017; 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AC, Kwong YI, Fu KH, et al. Disseminated mediastinal carcinoma with chromosomal translocation (15;19). A distinctive clinicopathologic syndrome. Cancer 1993; 72:2273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           French CA, Kutok JL, Faquin WC, et al. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol 2004; 22:4135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 2012; 18:5773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans AG, French CA, Cameron MJ, et al. Pathologic characteristics of NUT midline carcinoma arising in the mediastinum. Am J Surg Pathol 2012; 36:1222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           French CA, Miyoshi I, Kubonishi I, et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 2003; 63:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haack H, Johnson LA, Fry CJ, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol 2009; 33:984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki S, Kurabe N, Ohnishi I, et al. NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue. Pathol Res Pract 2015; 211:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasserjian RP, Klimstra DS, Rosai J. Carcinoma of the thymus with clear-cell features. Report of eight cases and review of the literature. Am J Surg Pathol 1995; 19:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dai X, Zhao L, Peng F. Primary clear cell carcinoma of the thymus and literature comparison of features. Cancer Manag Res 2018; 10:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snover DC, Levine GD, Rosai J. Thymic carcinoma. Five distinctive histological variants. Am J Surg Pathol 1982; 6:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suster S, Moran CA. Primary synovial sarcomas of the mediastinum: a clinicopathologic, immunohistochemical, and ultrastructural study of 15 cases. Am J Surg Pathol 2005; 29:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baranov E, McBride MJ, Bellizzi AM, et al. A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma. Am J Surg Pathol 2020; 44:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roden AC, Ahmad U, Cardillo G, et al. Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group. J Thorac Oncol 2022; 17:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jha V, Sharma P, Mandal AK. Utility of Cluster of Differentiation 5 and Cluster of Differentiation 117 Immunoprofile in Distinguishing Thymic Carcinoma from Pulmonary Squamous Cell Carcinoma: A Study on 1800 Nonsmall Cell Lung Cancer Cases. Indian J Med Paediatr Oncol 2017; 38:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kriegsmann M, Muley T, Harms A, et al. Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases. Diagn Pathol 2015; 10:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suster S, Moran CA. Primary thymic epithelial neoplasms showing combined features of thymoma and thymic carcinoma. A clinicopathologic study of 22 cases. Am J Surg Pathol 1996; 20:1469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su XY, Wang WY, Li JN, et al. Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas. Int J Clin Exp Pathol 2015; 8:5354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khoury T, Chandrasekhar R, Wilding G, et al. Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma. Int J Exp Pathol 2011; 92:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angirekula M, Chang SY, Jenkins SM, et al. CD117, BAP1, MTAP, and TdT Is a Useful Immunohistochemical Panel to Distinguish Thymoma from Thymic Carcinoma. Cancers (Basel) 2022; 14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jia R, Sulentic P, Xu JM, Grossman AB. Thymic Neuroendocrine Neoplasms: Biological Behaviour and Therapy. Neuroendocrinology 2017; 105:105.
          </a>
         </li>
         <li class="breakAll">
          AJCC Cancer Staging Manual, 8th ed, Amin MB, Edge SB, Greene FL, et al. (Eds), Springer, Chicago 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weidner N. Germ-cell tumors of the mediastinum. Semin Diagn Pathol 1999; 16:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oosterhuis JW, Looijenga LH. Mediastinal germ cell tumors: many questions and perhaps an answer. J Clin Invest 2020; 130:6238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran CA, Suster S. Primary germ cell tumors of the mediastinum: I. Analysis of 322 cases with special emphasis on teratomatous lesions and a proposal for histopathologic classification and clinical staging. Cancer 1997; 80:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takeda S, Miyoshi S, Ohta M, et al. Primary germ cell tumors in the mediastinum: a 50-year experience at a single Japanese institution. Cancer 2003; 97:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee T, Seo Y, Han J, Kwon GY. Analysis of chromosome 12p over-representation and clinicopathological features in mediastinal teratomas. Pathology 2019; 51:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kao CS, Bangs CD, Aldrete G, et al. A Clinicopathologic and Molecular Analysis of 34 Mediastinal Germ Cell Tumors Suggesting Different Modes of Teratoma Development. Am J Surg Pathol 2018; 42:1662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Napieralska A, Majewski W, Osewski W, Miszczyk L. Primary mediastinal seminoma. J Thorac Dis 2018; 10:4335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran CA, Suster S, Przygodzki RM, Koss MN. Primary germ cell tumors of the mediastinum: II. Mediastinal seminomas--a clinicopathologic and immunohistochemical study of 120 cases. Cancer 1997; 80:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns BF, McCaughey WT. Unusual thymic seminomas. Arch Pathol Lab Med 1986; 110:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran CA, Suster S. Mediastinal seminomas with prominent cystic changes. A clinicopathologic study of 10 cases. Am J Surg Pathol 1995; 19:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fichtner A, Richter A, Filmar S, et al. Primary mediastinal germ cell tumours: an immunohistochemical and molecular diagnostic approach. Histopathology 2022; 80:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iczkowski KA, Butler SL, Shanks JH, et al. Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors. Hum Pathol 2008; 39:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxman S, Nichols CR, Williams SD, et al. Mediastinal yolk sac tumor. The Indiana University experience, 1976 to 1988. J Thorac Cardiovasc Surg 1991; 102:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran CA, Suster S, Koss MN. Primary germ cell tumors of the mediastinum: III. Yolk sac tumor, embryonal carcinoma, choriocarcinoma, and combined nonteratomatous germ cell tumors of the mediastinum--a clinicopathologic and immunohistochemical study of 64 cases. Cancer 1997; 80:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran CA, Suster S. Primary mediastinal choriocarcinomas: a clinicopathologic and immunohistochemical study of eight cases. Am J Surg Pathol 1997; 21:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dehner LP. Germ cell tumors of the mediastinum. Semin Diagn Pathol 1990; 7:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malagón HD, Valdez AM, Moran CA, Suster S. Germ cell tumors with sarcomatous components: a clinicopathologic and immunohistochemical study of 46 cases. Am J Surg Pathol 2007; 31:1356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sung MT, Maclennan GT, Lopez-Beltran A, et al. Primary mediastinal seminoma: a comprehensive assessment integrated with histology, immunohistochemistry, and fluorescence in situ hybridization for chromosome 12p abnormalities in 23 cases. Am J Surg Pathol 2008; 32:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           den Bakker MA, Marx A, Mukai K, Ströbel P. Mesenchymal tumours of the mediastinum--part I. Virchows Arch 2015; 467:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           den Bakker MA, Marx A, Mukai K, Ströbel P. Mesenchymal tumours of the mediastinum--part II. Virchows Arch 2015; 467:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marchevsky AM. Mediastinal tumors of peripheral nervous system origin. Semin Diagn Pathol 1999; 16:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu YR, Torres-Mora J, Kipp BR, et al. Clinicopathological, immunophenotypic and genetic studies of mediastinal paragangliomas†. Eur J Cardiothorac Surg 2019; 56:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 2011; 96:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boedeker CC. Paragangliomas and paraganglioma syndromes. GMS Curr Top Otorhinolaryngol Head Neck Surg 2011; 10:Doc03.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welander J, Söderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 2011; 18:R253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshida A, Kobayashi E, Kubo T, et al. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol 2017; 30:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sauter JL, Graham RP, Larsen BT, et al. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Mod Pathol 2017; 30:1422.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4613 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31870881" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Distribution of Mediastinal Lesions Across Multi-Institutional, International, Radiology Databases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2268436" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pitfalls in intraoperative frozen section histology of mediastinal neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28129068" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : ITMIG Classification of Mediastinal Compartments and Multidisciplinary Approach to Mediastinal Masses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28129068" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : ITMIG Classification of Mediastinal Compartments and Multidisciplinary Approach to Mediastinal Masses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7872428" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Primary intrapulmonary thymoma. A clinicopathologic and immunohistochemical study of eight cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1733348" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Thymomas presenting as pleural tumors. Report of eight cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29626459" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : An Unusual Invasive Ectopic Thymoma in the Thyroid and Anterior Mediastinum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29312764" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Ectopic thymoma managed by neck dissection&amp;video-assisted thoracoscopic thymectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12124843" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25634747" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12459627" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Correlation of the WHO schema for the classification of thymic epithelial neoplasms with prognosis: a retrospective study of 90 tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25629638" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Modified Masaoka stage and size are independent prognostic predictors in thymoma and modified Masaoka stage is superior to histopathologic classifications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25629638" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Modified Masaoka stage and size are independent prognostic predictors in thymoma and modified Masaoka stage is superior to histopathologic classifications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25382290" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Type A and AB thymomas: histological features associated with increased stage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23579619" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The role of histology in predicting recurrence of type A thymomas: a clinicopathologic correlation of 23 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23579619" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The role of histology in predicting recurrence of type A thymomas: a clinicopathologic correlation of 23 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26295375" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8042589" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Plasma cell-rich thymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8333562" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Rhabdomyomatous thymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3677008" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Thymoma. A clinicopathologic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29438696" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The Integrated Genomic Landscape of Thymic Epithelial Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28676218" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : GTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32923872" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A-MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31641231" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24134933" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Analysis of MAML2 rearrangement in mucoepidermoid carcinoma of the thymus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35319525" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Thymic Mucoepidermoid Carcinoma: A Clinicopathologic and Molecular Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34354947" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : YAP1-MAML2 Fusion as a Diagnostic Biomarker for Metaplastic Thymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28179162" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22357254" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22825469" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27844328" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28212996" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31050844" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : EWSR1 translocation in primary hyalinising clear cell carcinoma of the thymus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2420219" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : An immunohistochemical study of thymic epithelial tumors. I. Epithelial component.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7573670" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3789252" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : An immunohistochemical study of thymic epithelial tumors. II. Lymphoid component.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26189704" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Thyroid transcription factor-1 immunostaining in World Health Organization type AB thymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24722150" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8044305" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3181952" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Cortical versus medullary thymomas: a useful morphologic distinction?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23319214" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Thymic carcinomas: clinicopathologic study of 37 cases from a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23225512" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Thymomas and thymic carcinomas: prognostic factors and multimodal management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15111216" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Thymic tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1991250" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Thymic carcinoma. A clinicopathologic study of 60 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1689123" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Thymic carcinoma. A clinicopathologic study of 13 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7793481" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Mucoepidermoid carcinomas of the thymus. A clinicopathologic study of six cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7872253" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2985993" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Association of Epstein-Barr virus with thymic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28942409" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A rare highly aggressive tumour: lymphoepithelioma-like thymic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8374886" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Disseminated mediastinal carcinoma with chromosomal translocation (15;19). A distinctive clinicopathologic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15483023" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Midline carcinoma of children and young adults with NUT rearrangement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22896655" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Clinicopathologic features and long-term outcomes of NUT midline carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22790861" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Pathologic characteristics of NUT midline carcinoma arising in the mediastinum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12543779" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19363441" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25466466" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7793482" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Carcinoma of the thymus with clear-cell features. Report of eight cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29588619" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Primary clear cell carcinoma of the thymus and literature comparison of features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7125053" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Thymic carcinoma. Five distinctive histological variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15832079" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Primary synovial sarcomas of the mediastinum: a clinicopathologic, immunohistochemical, and ultrastructural study of 15 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32141887" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35227908" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29333007" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Utility of Cluster of Differentiation 5 and Cluster of Differentiation 117 Immunoprofile in Distinguishing Thymic Carcinoma from Pulmonary Squamous Cell Carcinoma: A Study on 1800 Nonsmall Cell Lung Cancer Cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26643918" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8944040" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Primary thymic epithelial neoplasms showing combined features of thymoma and thymic carcinoma. A clinicopathologic study of 22 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26191237" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21044186" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35565429" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : CD117, BAP1, MTAP, and TdT Is a Useful Immunohistochemical Panel to Distinguish Thymoma from Thymic Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28355610" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Thymic Neuroendocrine Neoplasms: Biological Behaviour and Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28355610" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Thymic Neuroendocrine Neoplasms: Biological Behaviour and Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10355653" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Germ-cell tumors of the mediastinum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33196463" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Mediastinal germ cell tumors: many questions and perhaps an answer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9264351" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Primary germ cell tumors of the mediastinum: I. Analysis of 322 cases with special emphasis on teratomatous lesions and a proposal for histopathologic classification and clinical staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12518361" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Primary germ cell tumors in the mediastinum: a 50-year experience at a single Japanese institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30470411" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Analysis of chromosome 12p over-representation and clinicopathological features in mediastinal teratomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30256256" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A Clinicopathologic and Molecular Analysis of 34 Mediastinal Germ Cell Tumors Suggesting Different Modes of Teratoma Development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30174881" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Primary mediastinal seminoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9264352" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Primary germ cell tumors of the mediastinum: II. Mediastinal seminomas--a clinicopathologic and immunohistochemical study of 120 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3754728" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Unusual thymic seminomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7661278" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Mediastinal seminomas with prominent cystic changes. A clinicopathologic study of 10 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34506648" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Primary mediastinal germ cell tumours: an immunohistochemical and molecular diagnostic approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18045648" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1960997" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Mediastinal yolk sac tumor. The Indiana University experience, 1976 to 1988.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9264353" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Primary germ cell tumors of the mediastinum: III. Yolk sac tumor, embryonal carcinoma, choriocarcinoma, and combined nonteratomatous germ cell tumors of the mediastinum--a clinicopathologic and immunohistochemical study of 64 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9298876" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Primary mediastinal choriocarcinomas: a clinicopathologic and immunohistochemical study of eight cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2178277" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Germ cell tumors of the mediastinum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17721191" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Germ cell tumors with sarcomatous components: a clinicopathologic and immunohistochemical study of 46 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18162782" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Primary mediastinal seminoma: a comprehensive assessment integrated with histology, immunohistochemistry, and fluorescence in situ hybridization for chromosome 12p abnormalities in 23 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26358059" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Mesenchymal tumours of the mediastinum--part I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26358060" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Mesenchymal tumours of the mediastinum--part II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10355655" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Mediastinal tumors of peripheral nervous system origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31329844" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Clinicopathological, immunophenotypic and genetic studies of mediastinal paragangliomas†.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21190975" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22558053" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Paragangliomas and paraganglioma syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22041710" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28256572" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28643792" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
